The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Abstract
Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. This study demonstrates that the trifunctional bsAb BiLu is able to kill tumor cells very efficiently without any additional costimulation of effector cells in vitro and in vivo. Remarkably, this bsAb also induces a long-lasting protective immunity against the targeted syngeneic mouse tumors (B16 melanoma and A20 B-cell lymphoma, respectively). A strong correlation was observed between the induction of a humoral immune response with tumor-reactive antibodies and the survival of mice. This humoral response was at least in part tumor specific as shown in the A20 model by the detection of induced anti-idiotype antibodies. Both the survival of mice and antitumor titers were significantly diminished when F(ab′)2 fragments of the same bsAb were applied, demonstrating the importance of the Fc region in this process. With the use of T-cell depletion, a contribution of a cellular antitumor response could be demonstrated. These results reveal the necessity of the Fc region of the bsAb with its potent immunoglobulin subclass combination mouse immunoglobulin G2a (IgG2a) and rat IgG2b. The antigen-presenting system seems to be crucial for achieving an efficient tumor cell killing and induction of long-lasting antitumor immunity. Hereby, the recruitment and activation of accessory cells by the intact bsAb is essential.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal studies, 100% of mice administered an injection of 4 μg of triomabs survived after intraperitoneal (IP) injection of a lethal dose of EpCAM + melanoma cells. 25”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [25]
In the citing paper
“All mice rechallenged on day 144 after the primary challenge were still able to reject the tumor, indicating the high efficacy and long duration of the antitumor response.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [25]
In the citing paper
“This effect was dependent on the presence of the hybrid Fc, and involved a humoral response directed against the non-transfected (EPCAM -) tumor cells.”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [25]
Citations
Cites
1 retracted
Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Müller, C. A., Becker, V., et al. (2000) · Nature Medicine · doi:10.1038/73193 · Cited by 637
RetractedDranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., et al. (1999) · Nature Medicine · doi:10.1038/13928 · Cited by 591
Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
Gong, J., Chen, D., Kashiwaba, M., & Kufe, D. W. (1997) · Nature Medicine · doi:10.1038/nm0597-558 · Cited by 591
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule.
Litvinov, S. V., Velders, M. P., Bakker, H. A. M., Fleuren, G. J., & Warnaar, S. O. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.125.2.437 · Cited by 525
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
French, R. R., Chan, H. T. C., Tutt, A. L., & Glennie, M. J. (1999) · Nature Medicine · doi:10.1038/8426 · Cited by 426
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213
Self-citationZeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204
Self-citationHeo, D. S., Park, J. G., Hata, K., Day, R., Herberman, R. B., & Whiteside, T. L. (1990) · PubMed · Cited by 192
Zeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189
Self-citation
Cited by
Sorted by citations
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 603
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknavičienė, B., Razbadauskas, A., Gore, M. E., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 548
Self-citationMonoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 435
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Bispecific antibodies: design, therapy, perspectives
Sedykh, S. E., Prinz, V. Y., Buneva, V. N., & Nevinsky, G. A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 297
Antibody-Based Immunotherapy of Cancer
Weiner, L. M., Murray, J. C., & Shuptrine, C. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.034 · Cited by 283
Seimetz, D., Lindhofer, H., & Bokemeyer, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.001 · Cited by 289
Self-citationCatumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274
Burges, A., Wimberger, P., Kümper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., Pfisterer, J., Lichinitser, M., Makhson, A., Moiseyenko, V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2769 · Cited by 257
Self-citationBispecific antibodies for cancer therapy: A review
Krishnamurthy, A., & Jimeno, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.002 · Cited by 229
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01581-2 · Cited by 229
Kiewe, P. M., Hasmüller, S., Kahlert, S., Heinrigs, M., Rack, B. K., Marmé, A., Korfel, A., Jäger, M., Lindhofer, H., Sommer, H. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2436 · Cited by 199
Self-citationAntibody-based therapies for malaria
Pleass, R. J., & Holder, A. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1267 · Cited by 182
McEnaney, P. J., Parker, C. G., Zhang, A. X., & Spiegel, D. A. (2012) · ACS Chemical Biology · doi:10.1021/cb300119g · Cited by 155
Structural and functional characterization of the trifunctional antibody catumaxomab
Chelius, D., Ruf, P., Gruber, P., Plöscher, M., Liedtke, R., Gansberger, E., Heß, J., Wasiliu, M., & Lindhofer, H. (2010) · mAbs · doi:10.4161/mabs.2.3.11791 · Cited by 145
Self-citationBispecific Antibodies for Cancer Immunotherapy: Current Perspectives
Müller, D., & Kontermann, R. E. (2010) · BioDrugs · doi:10.2165/11530960-000000000-00000 · Cited by 137
Immunotherapy of malignant ascites with trifunctional antibodies
Heiss, M. M., Ströhlein, M. A., Jäger, M., Kimmig, R., Burges, A., Schoberth, A., Jauch, K., Schildberg, F., & Lindhofer, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21165 · Cited by 117
Self-citationRecombinant antibodies for cancer diagnosis and therapy
Souriau, C., & Hudson, P. J. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.305 · Cited by 109
Ruf, P., Gires, O., Jäger, M., Fellinger, K., Atz, J., & Lindhofer, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603881 · Cited by 102
Self-citationSebastian, M., Passlick, B., Friccius-Quecke, H., Jäger, M., Lindhofer, H., Kanniess, F., Wiewrodt, R. G., Thiel, E., Buhl, R., & Schmittel, A. H. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0310-7 · Cited by 100
Self-citationPrinciples and Current Clinical Landscape of Multispecific Antibodies against Cancer
Elshiaty, M., Schindler, H., & Christopoulos, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115632 · Cited by 102
Chaudry, M. A., Sales, K. M., Ruf, P., Lindhofer, H., & Winslet, M. C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603505 · Cited by 97
Self-citationJäger, M., Schoberth, A., Ruf, P., Hess, J., & Lindhofer, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2861 · Cited by 94
Self-citationTargeting the neural cell adhesion molecule in cancer
Jensen, M., & Berthold, F. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.09.004 · Cited by 90
Ruf, P., Kluge, M., Jäger, M., Burges, A., Volovat, C. D., Heiss, M. M., Hess, J., Wimberger, P., Brandt, B., & Lindhofer, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03635.x · Cited by 88
Self-citationSymmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
Riethmüller, G. (2012) · Europe PMC (PubMed Central) · Cited by 85
Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.004 · Cited by 85
Bispecific antibody platforms for cancer immunotherapy
Lameris, R., de Bruin, R. C. G., Schneiders, F. L., Henegouwen, P. M. P. V. B. E., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.003 · Cited by 85
Ott, M., Marmé, F., Moldenhauer, G., Lindhofer, H., Hennig, M., Spannagl, R., Essing, M. M., Linke, R., & Seimetz, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26258 · Cited by 77
Self-citationBispecific Antibodies: Molecules That Enable Novel Therapeutic Strategies
Fischer, N., & Léger, O. J. P. (2007) · Pathobiology · doi:10.1159/000101046 · Cited by 80
Ströhlein, M. A., Lordick, F., Rüttinger, D., Grützner, K. U., Schemanski, O. C., Jäger, M., Lindhofer, H., Hennig, M., Jauch, K., Peschel, C., et al. (2011) · Onkologie · doi:10.1159/000324667 · Cited by 73
Self-citationT Cell–Activating Bispecific Antibodies in Cancer Therapy
Trabolsi, A., Arumov, A., & Schatz, J. H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900496 · Cited by 71
Stanglmaier, M., Faltin, M., Ruf, P., Bodenhausen, A., Schröder, P., & Lindhofer, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.23626 · Cited by 66
Self-citationSebastian, M., Kiewe, P. M., Schuette, W., Brust, D., Peschel, C., Schneller, F., Rühle, K.-H., Nilius, G., Ewert, R., Lodziewski, S., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318195b5bb · Cited by 65
Self-citationAldeghaither, D. S., Smaglo, B. G., & Weiner, L. M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.407 · Cited by 68
Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy
Fucà, G., Spagnoletti, A., Ambrosini, M., de Braud, F., & Nicola, M. D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100046 · Cited by 64
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
Mantia-Smaldone, Edwards, & Vlad, A. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8759 · Cited by 63
Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M. A., Ottmann, O. G., Ruf, P., Lindhofer, H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2449-0 · Cited by 63
Self-citationWorld Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
Dhimolea, E., & Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.4.1.18821 · Cited by 58
Ertumaxomab: a trifunctional antibody for breast cancer treatment
Kiewe, P. M., & Thiel, E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1553 · Cited by 56
Schlereth, B., Kleindienst, P., Fichtner, I., Lorenczewski, G., Brischwein, K., Lippold, S., da Silva, A., Locher, M., Kischel, R., Lutterbüse, R., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0082-x · Cited by 55
Two new trifunctional antibodies for the therapy of human malignant melanoma
Ruf, P., Jäger, M., Ellwart, J., Wosch, S., Kusterer, E., & Lindhofer, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11630 · Cited by 52
Self-citationBispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer
Fournier, P., & Schirrmacher, V. (2012) · BioDrugs · doi:10.1007/s40259-012-0008-z · Cited by 55
Ströhlein, M. A., Siegel, R., Jäger, M., Lindhofer, H., Jauch, K., & Heiss, M. M. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-18 · Cited by 52
Self-citationBerek, J. S., Edwards, R. P., Parker, L. P., DeMars, L. R., Herzog, T. J., Lentz, S. S., Morris, R. T., Akerley, W., Holloway, R. W., Method, M. W., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000286 · Cited by 51
Baumann, K., Pfisterer, J., Wimberger, P., Burchardi, N., Kurzeder, C., du Bois, A., Loibl, S., Sehouli, J., Huober, J., Schmalfeldt, B., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.06.004 · Cited by 49
Buhmann, R., Simoes, B., Stanglmaier, M., Yang, T., Faltin, M., Bund, D., Lindhofer, H., & Kolb, H.-J. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.323 · Cited by 48
Self-citationCatumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites
Bokemeyer, C. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.504706 · Cited by 47
Test System for Trifunctional Antibodies in 3D MCTS Culture
Hirschhaeuser, F., Leidig, T., Rodday, B., Lindemann, C., & Mueller‐Klieser, W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109341766 · Cited by 47
“NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results
Thakur, A. B., & Lum, L. G. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1150996 · Cited by 46
Salnikov, A. V., Groth, A., Apel, A., Kallifatidis, G., Beckermann, B. M., Khamidjanov, A., Ryschich, E., Büchler, M. W., Herr, I., & Moldenhauer, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00723.x · Cited by 45
Timm, V., Gruber, P., Wasiliu, M., Lindhofer, H., & Chelius, D. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.01.036 · Cited by 43
Self-citationFrampton, J. E. (2012) · Drugs · doi:10.2165/11209040-000000000-00000 · Cited by 42
Natsume, A., Wakitani, M., Yamane‐Ohnuki, N., Shoji-Hosaka, E., Niwa, R., Uchida, K., Satoh, M., & Shitara, K. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj157 · Cited by 42
Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect
Eißler, N., Ruf, P., Mysliwietz, J., Lindhofer, H., & Mocikat, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0146 · Cited by 41
Self-citationPast, Present and Future Targets For Immunotherapy in Ovarian Cancer
Schwab, C. L., English, D. P.-G., Roque, D. M., Pasternak, M. C., & Santin, A. D. (2014) · Immunotherapy · doi:10.2217/imt.14.90 · Cited by 42
Emerging treatment options for management of malignant ascites in patients with ovarian cancer
Tewari, K. S., & Eskander, R. N. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s29467 · Cited by 41
The intriguing options of multispecific antibody formats for treatment of cancer.
Weidle, U. H., Tiefenthaler, G., Weiss, E. H., Georges, G. J., & Brinkmann, U. (2013) · PubMed · Cited by 40
Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Ruf, P., & Slavin, S. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.03.005 · Cited by 38
Self-citationClinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors
Gu, Y., & Zhao, Q. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00734-w · Cited by 38
Tita‐Nwa, F., Moldenhauer, G., Herbst, M., Kleist, C., Ho, A. D., & Kornacker, M. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0333-0 · Cited by 38
Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
Liu, M., Li, Z., Yang, J., Jiang, Y., Chen, Z., Ali, Z., He, N., & Wang, Z. (2016) · Cell Proliferation · doi:10.1111/cpr.12266 · Cited by 37
Buhmann, R., Stanglmaier, M., Heß, J., Lindhofer, H., Peschel, C., & Kolb, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-160 · Cited by 35
Self-citationSchuster, F. R., Stanglmaier, M., Woessmann, W., Winkler, B., Siepermann, M., Meisel, R., Schlegel, P. G., Hess, J., Lindhofer, H., Borkhardt, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13242 · Cited by 33
Self-citationCancer research and therapy: Where are we today?
Sawant, S., & Shegokar, R. (2014) · International Journal of Cancer Therapy and Oncology · doi:10.14319/ijcto.0204.8 · Cited by 32
Cancer Therapy with Trifunctional Antibodies: Linking Innate and Adaptive Immunity
Heß, J., Ruf, P., & Lindhofer, H. (2011) · Future Oncology · doi:10.2217/fon.11.138 · Cited by 30
Self-citationRuf, P., Schäfer, B., Eißler, N., Mocikat, R., Heß, J., Plöscher, M., Wosch, S., Suckstorff, I., Zehetmeier, C., & Lindhofer, H. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-219 · Cited by 30
Self-citationRiechelmann, H., Wiesneth, M., Schauwecker, P., Reinhardt, P., Gronau, S., Schmitt, A., Schroen, C., Atz, J., & Schmitt, M. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0283-6 · Cited by 30
New Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukaemia
Schriever, F., & Huhn, D. (2003) · Drugs · doi:10.2165/00003495-200363100-00003 · Cited by 29
Fossati, M., Buzzonetti, A., Monego, G., Catzola, V., Scambia, G., Fattorossi, A., & Battaglia, A. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.003 · Cited by 28
Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., & Slavin, S. (2005) · Blood · doi:10.1182/blood-2005-07-2738 · Cited by 28
Self-citationZou, H., Mou, X., & Zhu, B. (2022) · Global Challenges · doi:10.1002/gch2.202200094 · Cited by 31
Atanackovic, D., Reinhard, H., Meyer, S., Spöck, S., Grob, T. J., Luetkens, T., Yousef, S., Cao, Y., Hildebrandt, Y., Templin, J., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26065 · Cited by 25
The current status of immunotherapy in peritoneal carcinomatosis
Ströhlein, M. A., Heiss, M. M., & Jauch, K. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1224666 · Cited by 25
Witthauer, J., Schlereth, B., Brischwein, K., Winter, H., Funke, I., Jauch, K., Baeuerle, P. A., & Mayer, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0185-0 · Cited by 23
Wen, Q., Xiong, W., He, J., Zhang, S., Du, X., Liu, S., Wang, J., Zhou, M., & Ma, L. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0799-7 · Cited by 23
Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature
Mo, S., & Cai, G. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/1516259 · Cited by 23
Targeting Solid Tumors Using CD3 Bispecific Antibodies
Crawford, A., & Chiu, D. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0073 · Cited by 22
Carrasco‐Padilla, C., Hernaiz-Esteban, A., Álvarez‐Vallina, L., Aguilar-Sopeña, Ó., & Roda‐Navarro, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010132 · Cited by 23
Syed, Y. Y. (2025) · Drugs · doi:10.1007/s40265-025-02187-9 · Cited by 21
Ströhlein, M. A., & Heiss, M. M. (2010) · Future Oncology · doi:10.2217/fon.10.111 · Cited by 21
Zirngibl, F., Ivasko, S. M., Grunewald, L., Klaus, A., Schwiebert, S., Ruf, P., Lindhofer, H., Astrahantseff, K., Andersch, L., Schulte, J. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002923 · Cited by 23
Self-citationAntitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?
Maher, J. F., & Adami, A. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1852 · Cited by 20
Emoto, S., Sunami, E., Yamaguchi, H., Ishihara, S., Kitayama, J., & Watanabe, T. (2014) · Surgery Today · doi:10.1007/s00595-014-0848-x · Cited by 20
Tewari, K. S., & Eskander, R. N. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s45885 · Cited by 20
Heiss, M. M., Ströhlein, M. A., Bokemeyer, C., Arnold, D., Parsons, S. L., Seimetz, D., Lindhofer, H., Schulze, E., & Hennig, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2351 · Cited by 20
Self-citationTargeted molecular therapies for ovarian cancer: An update and future perspectives (Review)
Shigetomi, H., Higashiura, Y., Kajihara, H., & Kobayashi, H. (2012) · Oncology Reports · doi:10.3892/or.2012.1833 · Cited by 18
Sehouli, J., Pietzner, K., Wimberger, P., Vergote, I. B., Rosenberg, P., Schneeweiß, A., Bokemeyer, C., Salat, C., Scambia, G., Berton-Rigaud, D., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0076-7 · Cited by 18
Groth, A., Salnikov, A. V., Ottinger, S., Gladkich, J., Liu, L., Kallifatidis, G., Salnikova, O. V., Ryschich, E., Giese, N. A., Giese, T., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2767 · Cited by 19
Deppisch, N., Ruf, P., Eißler, N., Neff, F., Buhmann, R., Lindhofer, H., & Mocikat, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0156 · Cited by 18
Self-citationInfluence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Wimberger, P., Heubner, M. L., Lindhofer, H., Jäger, M., Kimmig, R., & Kasimir‐Bauer, S. (2009) · PubMed · Cited by 18
Self-citationStemmler, H., Salat, C., Lindhofer, H., Menzel, H., Untch, M., Kahlert, S., Konecny, G., Sauer, H., Ledderose, G., Heinemann, V., et al. (2005) · PubMed · Cited by 18
Self-citationBispecific antibodies for the treatment of breast cancer
Dillon, P. M., Tushir‐Singh, J., & Lum, L. G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1922665 · Cited by 18
Sehouli, J., Reinthaller, A., Marth, C., Reimer, D., Reimer, T., Stummvoll, W., Angleitner-Boubenizek, L., Brandt, B., & Chekerov, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.443 · Cited by 16
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies
Safdari, Y., Ahmadzadeh, V., & Farajnia, S. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0349-4 · Cited by 15
Treatment options in chronic lymphocytic leukemia
Montserrat, E. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200386 · Cited by 15
Diermeier‐Daucher, S., Ortmann, O., Buchholz, S., & Brockhoff, G. (2012) · mAbs · doi:10.4161/mabs.21003 · Cited by 14
Ströhlein, M. A., Lefering, R. L., Bulian, D. R., & Heiss, M. M. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2013.12.014 · Cited by 14
Metadata
- Authors
- Ruf, P., & Lindhofer, H.
- Affiliations
- Helmholtz Munich (DE)
- ORCID
- Ruf, Peter
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-10-15
- Volume
- 98
- Issue
- 8
- Pages
- 2526-2534
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1972848082
- Cited by
- 174
- References
- 34
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 11 · 2015: 9 · 2014: 15 · 2013: 9 · 2012: 16
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- bispecific antibodies, trifunctional antibody, antitumor immunity, Fc fragment, humoral immune response, anti-idiotypic antibodies, T cell depletion, antigen-presenting cells, B16 melanoma, tumor cell killing, immunoglobulin G2a, tumor-specific antibodies
- MeSH terms
- Animals, Antibodies, Neoplasm, Antibody Formation, Antibody Specificity, Cytotoxicity, Immunologic, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Immunoglobulin G, Immunoglobulin Idiotypes, Immunoglobulin Fab Fragments, Immunoglobulin Fc Fragments, Melanoma, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Survival Rate, Antibodies, Bispecific, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
